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Objectives: Asymptomatic Peripheral Arterial Disease (PAD) is associated with 
greater risk of acute cardiovascular events. American heart association and American 
college of cardiology clinical practice guidelines recommend low dose aspirin to 
reduce the cardiovascular events and mortality in PAD patients. As asymptomatic 
PAD often remains undiagnosed, opportunities for secondary prevention are missed 
in primary care. Therefore, there is a clinical need of early detection of asympto-
matic PAD and to initiate the appropriate preventive treatment. United States pre-
ventive services task force’s recommendation against screening is heavily criticized 
and expansion of the evidence base for PAD screening is recommended in 2011 in 
a focussed update of the guidelines. This study aims to determine the value of PAD 
screening using ankle brachial index test in high risk individuals using decision 
analytic modelling. MethOds: A Markov model was developed to evaluate the cost 
effectiveness of selective PAD screening in high risk individuals followed by preventive 
treatment compared to no screening and no preventive treatment. The analysis was 
conducted from the societal perspective using a lifetime time horizon. To address the 
parameter uncertainty, probabilistic sensitivity analysis was performed. Results: 
Screening and preventive treatment of identified PAD patients with low dose aspirin 
is a dominant strategy producing higher mean quality adjusted life years per patient 
for a lower lifetime cost. The cost effectiveness acceptability curves show that 100% 
simulations favour screening followed by preventive treatment at a willingness to 
pay threshold of 400 Euros. cOnclusiOns: This decision analysis suggests that the 
targeted screening and secondary prevention of cardiovascular events in the identi-
fied patients, is a highly cost effective public health intervention. This study results 
may provide one of the building blocks of evidence expansion for advocating PAD 
screening and to promote its more widespread use to detect and treat PAD patients.
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Objectives: Therapy persistence is important to achieve optimal clinical benefits 
of statin therapy. The aim of this study was to determine the cost-effectiveness 
of pharmaceutical care in community pharmacies, aimed to increase persistence 
with statin therapy for both primary and secondary prevention of cardiovascular 
events (CVEs). MethOds: The effectiveness of the Dutch pharmaceutical care pro-
gram MeMO on improving statin therapy persistence was measured in 500 patients 
and compared to 502 control patients. Time-investments of the program were also 
collected. Markov models with lifelong time-horizons were developed to estimate 
the influence of the program on CVEs: stroke, myocardial infarction (MI), revascu-
larization and mortality. The efficacy of statins, taken from large clinical trials in 
primary and secondary prevention, were adjusted for therapy persistence. A Dutch 
health care provider’s perspective was adopted for the analysis and probabilistic 
sensitivity analyses were performed. Results: Patients in the MeMO program had 
a lower risk for non-persistence, RR = 0.50 (0.40-0.63), the effect was similar in 
primary and secondary prevention. In a cohort of 1,000 patients, 60% of whom had 
a history of CVE, the MeMO program resulted in a reduction of 8 non-fatal strokes, 
2 fatal strokes, 16 non-fatal MIs, 7 fatal MIs and 14 revascularizations. Additional 
medication, disease management and intervention costs in the MeMO program 
were € 375,000; the cost-savings due to reduced CVEs were € 450,000. Thus, the MeMO 
program resulted in 83 quality-adjusted life-years (QALYs) gained and cost-savings 
of € 75,000. Clinical benefits and cost-savings were highest in the secondary preven-
tion population. cOnclusiOns: Pharmaceutical care in community pharmacies 
can improve statin therapy persistence, resulting in more optimal prevention of 
CVEs. The MeMO program resulted in considerable clinical benefits and overall 
cost-savings. Persistence and adherence improving programs in community phar-
macies may provide good value for money and health care insurers should consider 
reimbursing these activities in The Netherlands.
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Objectives: To estimate cost-effectiveness of ivabradine used in treatment of 
chronic heart failure in Poland, using model based on individual patient data from 
pivotal SHIFT trial adapted using contemporary real-life epidemiology, treatment 
pattern and cost country-specific data. MethOds: Economic model based on SHIFT 
trial was originally developed for the UK setting and published. Based on the model, 
in November 2012 NICE gave its positive guidance for the analysed technology in 
line with EMA registered indication, acknowledging a range of conservative assump-
tions. Current study utilizes the NICE model populated with most recently published 
local data. General mortality was estimated from Polish life tables for the year 
2010. Unit cost and expected rate of hospitalizations on standard treatment was 
based on publication in Polish Heart Journal. Standard treatment cost was based 
on official listing of reimbursed drugs. Average cost of ivabradine (5mg and 7.5mg, 
56 tabs) was based on popular drug database (Kamsoft, April 2013). Exchange rate 
of National Bank of Poland 1 EUR= 4.1759 PLN was applied (May 2013). Results: 
At current pharmacy price (55.60 EUR / 56 tabs), incremental cost-utility ratio for 
ivabradine on top of standard treatment vs standard treatment alone is estimated 
at 10 230 EUR / QALY, well below the official cost-effectiveness threshold defined at 
3*DGP per capita (25 336 EUR). Sensitivity analysis revealed that in order to exceed 
the cost-effectiveness threshold, price would have to be increased to 113.60 EUR 
(+104%). cOnclusiOns: Conservative analysis shows that ivabradine used on top 
of standard treatment (ACE inhibitor, beta-blocker, MR antagonist, ±diuretics) in 
trolled with ≥ 3 different classes of antihypertensive therapy). Catheter-based renal 
denervation (RDN) is a novel, minimally invasive therapy for treatment-resistant 
hypertension. The aim of this study was to assess the cost-utility of RDN as compared 
to current standard of care (SoC) for refractory hypertension in Belgium. MethOds: 
A lifetime state-transition, Markov model was used, with health-states encompass-
ing possible long-term consequences of hypertension: stroke, myocardial infarction, 
angina, heart failure, end-stage renal disease. Risk equations were used to calculate 
the risk of events with changing systolic blood pressure (SBP). Reductions in SBP 
following RDN vs. SoC pertain to the results of the Symplicity HTN-2 randomized 
controlled trial. The underlying modeled cohort was defined similar to the same trial: 
mean baseline SBP 178 mmHg, mean age 58 years, 34% with diabetes mellitus. Costs 
pertained to published economic evaluations or public tariffs and reflected the Belgian 
payer perspective. Costs and health outcomes were discounted at a rate of 3%, and 
1.5% respectively. Results: Projected lifetime costs were 21,743€ and 24,558€ in the 
SoC and RDN arms respectively, while total projected life years were 16.43 and 17.23. 
RDN increased patients’ quality of life with 0.93 quality-adjusted life years (QALYs) vs. 
SoC. This resulted in an incremental cost-utility ratio (ICUR) of 3,020€ /QALY. Results 
were most sensitive to changes in SBP reductions, and the cost of RDN procedure, but 
remained under a willingness to pay (WTP) threshold of 20,000€ /QALY. Probabilistic 
sensitivity analyses showed acceptable cost-effectiveness in 100% of cases, under a 
WTP threshold of 20,000€ /QALY. cOnclusiOns: Results of these analyses suggest 
that, under the current model settings, catheter-based RDN procedure could be a 
cost-effective strategy for resistant hypertension in Belgium.
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Objectives: To assess the impact of atorvastatin compared to simvastatin use in the 
Czech Republic on cardiovascular diseases (CVD), Life-Years Gained (LYG) and Quality-
Adjusted Life Years (QALY), based on the real proportional consumption of both statins 
in particular strengths (10 mg, 20 mg, 40 mg). MethOds: Life-time cost-effectiveness 
Markov cohort model was developed with 1 year cycle length and 5 health sates, i.e. 
Alive without CVD, Alive with experience of CVD, Non-fatal CVD, Fatal CVD and Death. 
The probability of transition among health states were derived from Framingham 
equations or from SCORE equations (probability of the first non/fatal CVD), Czech 
life-tables (background mortality) and international cohort studies (probability of 
subsequent CVD). Patients enter the model with base-line risk characteristics: age, 
proportions of males, diabetics, smokers, level of systolic blood pressure and choles-
terol (total and HDL) level. The efficacy data for particular statin and its strength were 
derived from latest meta-analyses. Drug acquisition costs of atorvastatin 10 mg and 
20 mg were 10% higher compared to simvastatin 20 mg and 40 mg. The costs of fatal, 
non-fatal CVD and one-year follow-up after CVD were 1,410 EUR, 1,460 EUR and 580 
EUR. Probabilistic sensitivity analysis (PSA) using a willingness to pay (WTP) threshold 
equal to 1 times GDP per capita (14,300 EUR) was applied. Results: Over a life-time 
horizon, atorvastatin compared to simvastatin provides 8.14 QALYs vs. 8.07 QALYs, 
11.33 LYG vs. 11,24 LYG, 44.8% vs. 46.3% of non-fatal CVD and 28.2% vs. 29.4% of fatal 
CVD. The increment of total costs was 330 EUR for atorvastatin, ICER for atorvastatin 
vs. simvastatin was then 4,720 EUR/ QALY. cOnclusiOns: The use of atorvastatin 
generates 0.07 QALYs more compared to simvastatin per patient in the Czech Republic. 
There is a 98.5% probability of atorvastatin being cost-effective at the selected WTP.
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Objectives: The decision on whether to use more expensive novel oral antico-
agulants (NOACs) or invest resources for quality improvement of warfarin therapy 
requires inputs of both clinical and economic outcome analyses. Outcomes of NOACs 
comparing to warfarin therapy at various levels of patient-time in therapeutic range 
(TTR) in patients with atrial fibrillation were examined from health care provider’s 
perspective. MethOds: A Markov model was designed to compare life-long eco-
nomic and treatment outcomes of warfarin and NOACs in a hypothetical cohort of 
65-year-old atrial fibrillation patients with CHADS2score 2 or above. Model inputs were 
derived from clinical trials published in literature. Outcome measure was incremental 
cost per quality-adjusted life-year (QALY) gained (ICER). Results: Expected cost and 
QALYs of NOACs were USD96,602 and 9.957, correspondingly, in base-case analysis. 
Using USD50,000 as the threshold of willingness-to-pay per QALY, NOACs therapy was 
cost-effective when TTR of warfarin therapy was 60%, or monthly cost of warfarin 
management increased by 1.5-fold or above to achieve 70% TTR. Warfarin therapy 
was cost-effective when TTR of warfarin was 70% with no increment in monthly cost 
of care, or when TTR reached 75% with monthly cost of warfarin care increased up 
to 2.5-fold. At TTR 60%, 70% and 75%, NOACs was cost-effective when monthly drug 
cost was < USD208, < USD135-200 and < USD96-160, respectively. 10,000 Monte Carlo 
simulations showed NOACs to be cost-effective in 77.2%, 52.7% and 31.7% of time at 
TTR of 60%, 70% and 75%, respectively. cOnclusiOns: Acceptance of NOACs as cost-
effective was highly depended upon drug cost, anticoagulation control for warfarin, 
and anticoagulation service cost.
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Objectives: Peripheral arterial disease is associated with significant adverse out-
comes, especially in patients with critical limb ischemia (CLI; stages III and IV). At 
6 months, the risk of amputation is 35%, and mortality 20%. In patients unsuitable 
for interventional therapy, treatment with prostanoids may help reduce the risk of 
adverse outcomes. We aimed to assess the average cost of alprostadil (prostaglan-
din E1) as treatment for patients with CLI compared with lumbar sympathectomy 
from the perspective of The Mexican Social Security Institute (IMSS). MethOds: 
In a clinical trial, alprostadil and lumbar sympathectomy showed similar response 
rates (Petronella P, et al. Nutr Metab Cardiovasc Dis 2004;14:186–92).Therefore, we 
conducted a cost minimization analysis based on the direct medical costs of alpros-
tadil (40 µg twice-daily or 60 µg once-daily) administered over 28 days versus lumbar 
sympathectomy. Relevant costs included acquisition and infusion for alprostadil, 
and surgical procedure besides hospitalization (9 days) for lumbar sympathectomy. 
Unit cost for infusion was assumed to be equivalent to an emergency visit at first 
level of care at IMSS; unit cost of the surgical procedure and standard hospital stay 
(per day) correspond to the official values for these items at the second level of care 
at IMSS. UCB Pharma provided the cost for alprostadil. All costs are in 2013 Mexican 
pesos (MXN; 12.88 MXN = 1 USD, 17.23 MXN = 1 Euro). Results: Costs per patient 
would be lower with both alprostadil 40 µg twice-daily ($59,640) and alprostadil 
60 µg once-daily ($37,884) than with lumbar sympathectomy ($66,084), leading to 
savings of $6,444 (9.8%) and $28,200 (42.7%), respectively. Alprostadil use remained 
cost-saving versus lumbar sympathectomy in most of the scenarios evaluated 
through sensitivity analysis. cOnclusiOns: These results suggest alprostadil is a 
cost saving intervention when compared with lumbar sympathectomy for patients 
with CLI from the Mexican public health care perspective.
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Objectives: The objective of this pharmacoeconomic evaluation was to determine 
whether apixaban, compared to warfarin, dabigatran and rivaroxaban in patients 
suitable for vitamin K antagonists (VKA), or to aspirin in VKA-unsuitable patients, 
is a cost-effective treatment for the prevention of stroke or systemic embolism (SE) 
in adult patients with non-valvular atrial fibrillation (AF) with one or more risk fac-
tors. MethOds: A Markov model was constructed consisting of 18 health states, 
using a 6-week cycle length and a lifetime time horizon. Baseline characteristics were 
taken from a 2011 GPRD study. Clinical inputs were derived from a network meta-anal-
ysis of the efficacy and bleeding outcomes from the three warfarin-controlled trials 
ARISTOTLE, RE-LY and ROCKET-AF, and the single aspirin-controlled trial AVERROES. 
Local unit costs and utility data were assigned to the appropriate model health states 
to calculate total Quality-Adjusted Life Years (QALYs) and costs. Univariate and proba-
bilistic sensitivity analyses (PSA) were conducted. Results: Apixaban was associated 
with an ICER vs warfarin of € 11,087. Against the less-commonly used anti-coagulants, 
apixaban was cost-effective against each at the € 45,000 willingness-to-pay thresh-
old. Apixaban provided more QALYs than all other therapies. Compared to warfarin, 
apixaban produced savings in avoided cost of stroke, intracranial haemorrhage, INR 
monitoring, and bleeding. Apixaban was cost-effective across all patient subgroups 
of INR control (centre Time in Therapeutic Range) and CHADS2stroke risk categories 
1 and 2. One-way sensitivity analyses, scenario analyses, and probabilistic sensitivity 
analyses confirmed that the findings were robust to changes in key parameters. The 
probability that apixaban was the most cost-effective therapy at a willingness-to-
pay threshold of € 45,000 per QALY was 93% and 100% in the VKA-suitable and VKA-
unsuitable populations, respectively. cOnclusiOns: Apixaban can be considered 
cost-effective for the prevention of stroke and SE in people with non-valvular AF, at 
a threshold of € 45,000/QALY, under standard decision rules.
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Objectives: Stroke prevention is the main goal in treating patients with atrial 
fibrillation (AF). Treatment with anticoagulants, such as vitamin-K antagonists 
(VKAs; e.g. warfarin and cumarines), was demonstrated to be an effective strat-
egy. However, even though VKAs are the current standard therapy recommended 
by different guidelines, the significant risk of bleeding and the requirement for 
a regular monitoring are limiting its use. Apixaban is a novel oral anticoagulant 
(NOAC) associated with significantly lower hazard rates for stroke/systemic embo-
lism, major hemorrhage and discontinuations, compared to VKAs. This study evalu-
ated the cost-effectiveness (CE) of apixaban compared to VKAs in the base-case 
analysis and alternatively to other NOACs for stroke prevention in non-valvular 
AF patients in The Netherlands. MethOds: A global Markov model developed by 
United BioSource Corporation was modified to reflect the use of oral anticoagulants 
in The Netherlands. The model used efficacy data from a published indirect treat-
ment comparison of NOACs and cost data from Dutch costing studies as inputs. 
Following health states were included in the model: non-valvular AF, primary and 
recurrent ischemic and hemorrhagic stroke, systemic embolism, myocardial infarc-
tion, intracranial hemorrhage, other major and non-major bleedings, treatment 
patients suffering from chronic heart failure is a highly cost-effective health tech-
nology in the Polish setting, according to the criterion defined in Reimbursement 
Law. Robustness of this finding is demonstrated by the fact that cost-effectiveness 
is retained even at a price double vs base-case.
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Objectives: Large randomized clinical trials (RCT) evidenced the benefits of statins 
in reducing major cardiovascular events in patients with established coronary heart 
disease (CHD). These multinational trials are likely to provide internally valid evi-
dence. Cost-effectiveness analysis based on single trials costs and effects are common 
and represent the potential net benefit of an intervention in a well-controlled environ-
ment. The aim of this study is to systematically review the cost-effectiveness studies 
based on statins single trials in patients with previous CHD. MethOds: We searched 
to identify all literature relating to the cost-effectiveness of statins in the secondary 
prevention in patients with established CHD. Only studies with the effectiveness data 
extracted from a single RCT and clinical outcomes such as quality assessment, mor-
tality or cardiovascular events rate were included. The cost per QALY was classified 
according to the WHO, following three categories of cost-effectiveness, Highly cost-
effective, Cost-effective and Not cost-effective, adjusted with GDP per capita based 
on purchasing power parity (constant 2005 international USD). Results: Twenty-one 
studies were included in the final analysis, covering a period range from 1996 to 
2009. 7 large RCTs represented the origin of efficacy data. Most of studies assumed 
a full compliance, the Markov models were used in 11 out 21 studies. Time horizon 
ranged from 5 years to time life, with 10 years being the predominant choice. 9 studies 
performed a cost-utility analysis and showed the average cost per QALY, 8 of them 
classified as highly cost-effective and 1 cost-effective. Cost per QALY was sensitive for 
drug price, time horizon and event rates, 6 of this models models worked with com-
posite endpoints. cOnclusiOns: Statins are highly cost-effective in patients with 
CHD when effect size came from single well designed RCTs. Models heterogeneity 
and composite endpoints can decrease the robustness of the results.
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Objectives: It has been suggested that radiofrequency catheter ablation could take 
priority over antiarrhythmic drugs as first-line treatment of paroxysmal AF, due to 
better efficiency, and fewer serious side effects. The objective of this study was to 
evaluate the cost-effectiveness of treating paroxysmal atrial fibrillation with radi-
ofrequency catheter ablation as first-line treatment. MethOds: A decision-analytic 
Markov model was developed to study long-term effects and costs of catheter abla-
tion compared to antiarrhythmic drugs as first-line treatment. Results: Small, 
positive clinical effects were found in the overall population, a gain of an average 
0.06 quality-adjusted life years (QALYs) to an incremental cost of € 3033, resulting in 
an incremental cost-effectiveness ratio of € 50 570/QALY. However, the incremental 
cost-effectiveness ratio of a 45-year-old patient was approximately € 3434/QALY, 
while a 65-year-old costs € 108 937 per QALY. cOnclusiOns: Radio-frequency cath-
eter ablation as first-line treatment is a cost-effective strategy for younger patients 
with paroxysmal atrial fibrillation. However, the cost-effectiveness of using catheter 
ablation as first-line therapy in older patients is uncertain, and in most of these 
cases antiarrhythmic drug therapy should be attempted before catheter ablation.
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Objectives: Portugal is facing an economic crisis that demands a tight control over 
all hospitals’ expenditures, namely with medical devices, whose market price is not 
yet regulated or documented. This study aims to describe the number and value of 
the Active-Implantable Cardiac Devices (AICD) bought by Portuguese hospitals in 
2011, as well as to quantify potential savings that can be obtained shifting utilisation 
from higher to lower prices. MethOds: In February 2012, 42 hospitals were asked 
by INFARMED – National Authority of Medicines and Health Products, IP, about the 
number, type and value of the AICD acquired, using an ad-hoc developed software. 
Potential savings analysis was performed at two levels: AICD sub-groups (according 
to Portuguese Medical Device Nomenclature) and individual device reference. Within 
each level, three cost-minimization scenarios were conceptualized based on the 
minimum price reported (scenario 1), the average between the average price and 
the minimum one (scenario 2) and the average price (scenario 3). Results: During 
2011, 73.8% of the hospitals enrolled (n= 31) bought AICD, comprising 16,815 devices, 
at a cost of 40,217,411 euros. In numbers, the most common AICD were pacemakers 
(44.8%), whereas cardioverter-defibrillators were related to a higher expenditure 
ratio (51.5% of total cost). Based on the AICD sub-groups analysis, the potential sav-
ings were 14.5 million euros in scenario 1 (44.1% of total cost), 7.4 million euros in 
scenario 2 (22.5%) and 1.8 million euros in scenario 3 (5.3%). Following this scenario 
order, the device reference approach estimated savings of 6.2 million euros (18.8%), 
3.4 million euros (10.3%) and 1.1 million euros (3.3%), respectively. cOnclusiOns: 
Significant potential savings were found, being greater when analysing AICD sub-
groups, assuming equal efficiency and safety for all devices within these clusters. 
Despite scenario 1 higher savings, scenario 2 seems the most realistic and feasible, 
when trying to accomplish a sustainable health care system.
